-
Media Release
Novartis drug Signifor® LAR shows superior efficacy in acromegaly patients not controlled on first generation somatostatin analogues
-
Media Release
Novartis drug Signifor® LAR shows superior efficacy in acromegaly patients not controlled on first generation somatostatin analogues
-
Media Release
Novartis reports new Phase III data showing secukinumab (AIN457) improved moderate-to-severe plaque psoriasis in patients
-
Media Release
Novartis reports new Phase III data showing secukinumab (AIN457) improved moderate-to-severe plaque psoriasis in patients
-
Media Release
Novartis Announces FDA Approval of Xolair® (omalizumab) for Chronic Idiopathic Urticaria (CIU), a Form of Chronic Hives
-
Media Release
Novartis Announces FDA Approval of Xolair® (omalizumab) for Chronic Idiopathic Urticaria (CIU), a Form of Chronic Hives
-
Media Release
Novartis Pharmaceuticals Corporation stands behind medication adherence activities and reaffirms commitment to patient safety
-
Media Release
Novartis Pharmaceuticals Corporation stands behind medication adherence activities and reaffirms commitment to patient safety
-
Media Release
Novartis highlights research on investigational, personalized T cell therapy CTL019 in patients with forms of acute and chronic leukemia
-
Media Release
Novartis highlights research on investigational, personalized T cell therapy CTL019 in patients with forms of acute and chronic leukemia
-
Media Release
Novartis Hosts Competition to Create Novel Mobile Solutions for Heart Failure Caregivers
-
Media Release
Novartis Hosts Competition to Create Novel Mobile Solutions for Heart Failure Caregivers